Integrative Approaches for Breast Cancer Survivorship

This study, called IACS3, is for people who have completed treatment for early-stage breast cancer (Anatomic Stage I, II, or III). It's looking at two different approaches to help survivors: one is called Ayurveda Intervention (AVI) and the other is Facing Forward Health Education Intervention (FFHEI). AVI involves nutrition education, lifestyle tips, yoga, and a type of therapeutic touch called marma therapy. FFHEI uses online videos and materials to provide health education. The main goal is to see if these programs are practical and acceptable for people to use, and if the study design works well across different locations. You must be at least 18 years old and able to understand English to participate.

Study design
This is a pilot randomized controlled trial with 106 participants. You would be randomly assigned to one of two groups: either the Ayurveda Intervention or the Facing Forward Health Education Intervention.
What's involved
If in the AVI group, you would have up to 14 one-on-one visits over 6 months, plus optional monthly videoconference visits for another 6 months. If in the FFHEI group, you would access up to 15 online sessions over 6 months.
Compensation
Not stated in the trial record.
Follow-up
The study will track certain information, like enrollment and dropout rates, for up to 15 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06633926

Integrative Approaches for Cancer Survivorship (IACS3)

Active, Not Recruiting
NAAges 18+InterventionalSupportive care
University of California, San Francisco
~107 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:Nutrition EducationLifestyle CounselingYogaMarma therapyEducational InterventionQuality of Life Questionnaire Administration

At a glance

Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of all screened participants who were ultimately enrolled
Measured over Up to 15 months
+9 more outcomes measured
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
4 sites across 2 states
California3
Tennessee1
  • Anand Dhruva, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

This trial hasn't published a contact. View it on ClinicalTrials.gov

  • Proportion of all screened participants who were ultimately enrolledUp to 15 months

    The proportion of all screened participants who were ultimately enrolled onto the study will be reported.

  • Proportion of eligible screens who decline to enrollUp to 15 months

    Proportion of eligible screens who decline to enroll due to concerns about randomization will be reported.

  • Proportion of enrolled participants who drop out immediately after assignmentUp to 15 months

    Proportion of enrolled participants who drop out after learning their randomization assignment will be reported.

  • Proportion of randomized participants who drop out during participationUp to 6 months

    Proportion of randomized participants who drop out after participating in the study interventions due to unhappiness with randomization assignment will be reported.

  • Retention ratesUp to 6 months

    The proportion of participants who complete \<=70% of study measures will be reported.

  • Adherence to intervention rateUp to 6 months

    Proportion of participants who attended at least 10 out of 14 sessions or completed 10 out of 14 HEI sessions (≥80%) will be reported

  • Practitioner fidelity ratesUp to 6 months

    Fidelity of adherence to the intervention will be assessed through a contact check-list method comparing the intervention to the study manuals and the rate of adherence will be reported.

  • Assessment completion ratesUp to 6 months

    Assessment completion rates will be defined as the percentage of participants completing each assessment.

  • Mean scores on an Acceptability of Intervention measureUp to 6 months

    The measure used for this study is a single item assessment of the implementation to participants perceived acceptability of the intervention. The response item response falls on a numeric rating scale of 0 to 10. A mean score is calculated by averaging responses from all participants. The intervention will be determined acceptable if the overall mean score is \>= 8.

  • Change in mean scores on an Expectation of Benefit questionnaire over timeUp to 6 months

    The change in participant's expectation of intervention benefit at baseline-pre and post randomization-will be assessed using a 0-10 numeric rating scale of 0 to 10. A mean score is calculated by averaging responses from all participants. The instrument for expectancy, is adapted from a measure created by Kalauokalani et. al, with higher scores indicating a higher level of expectation that the intervention will be beneficial.